Eli Lilly is undergoing leadership changes in its diabetes and obesity division as it anticipates a significant FDA decision in the obesity field. After 34 years with the company, Mike Mason, president of Lilly Diabetes and Obesity, is retiring and will be succeeded by Patrik Jonsson on January 1.
Patrik Jonsson, a 33-year veteran at Lilly, will continue to serve as president of Lilly USA while taking on the role of president of Lilly Diabetes and Obesity. In this dual capacity, Jonsson will oversee Lilly’s existing products and late-stage portfolio of diabetes and obesity medications, including the promising Mounjaro.
Also Read: Sage Slashes 40% Of Staff, Reshuffles Leadership After Zuranolone Setback
As part of the restructuring, Jonsson will step down from his position as Chief of Lilly Immunology. The new head of Lilly Immunology will be Daniel Skovronsky, M.D., Ph.D., who will retain his roles as Chief Scientific Officer and President of Lilly Research Laboratories. Skovronsky’s expanded responsibilities will encompass Lilly’s dermatology, gastroenterology, and rheumatology products that are either launched or in late-stage development.
David Ricks, CEO of Lilly, expressed confidence in the leadership team’s depth of experience and its ability to drive the company’s efforts forward in innovative ways.
Leigh Ann Pusey, EVP of Corporate Affairs and Communications at Lilly, will depart at the end of the year. Her responsibilities will be assigned to other executive committee members. Pusey, who joined Lilly in 2017 after serving as President and CEO of the American Insurance Association for eight years, will be pursuing another opportunity in Washington, D.C.
Also Read: Pfizer Reveals Executive Leadership To Advance Its Oncology R&D Strategy
In connection with these changes, Lilly has recruited Mark Genovese, M.D., previously Senior VP of Inflammation Development at Gilead Sciences and a professor at Stanford University. Genovese will join Lilly on October 16 as Senior VP of Immunology Development, overseeing Lilly’s mid- and late-stage immunology portfolio.
David Hyman, M.D., will assume the role of Lilly’s Chief Medical Officer, reporting to Daniel Skovronsky, and will continue to lead oncology development. Additionally, Jennifer Oleksiw has been promoted to Group VP, Global Chief Customer Officer, reporting to David Ricks.
